Journal of Vaccine Research 2024, Vol.14, No.4, 157-169 http://medscipublisher.com/index.php/jvr 161 4.3 Computational approaches Computational approaches have become indispensable in the field of vaccine design, particularly for developing universal influenza vaccines. These approaches leverage the power of bioinformatics, structural biology, and machine learning to predict, model, and optimize vaccine candidates that can elicit broad and long-lasting immunity. Given the rapid evolution and genetic diversity of influenza viruses, traditional empirical methods have often fallen short in providing effective solutions. In contrast, computational approaches allow for the rational design of immunogens that target conserved regions of the virus, offering a promising path toward a universal vaccine (Zost et al., 2019; Goff et al., 2015). One of the most significant contributions of computational approaches is the development of Computationally Optimized Broadly Reactive Antigens (COBRA). COBRA utilizes consensus sequence algorithms and phylogenetic models to design antigens that can induce cross-reactive immune responses against a wide array of influenza strains. This method has proven effective in creating vaccines that provide protection against both seasonal and pandemic strains of influenza, as demonstrated in preclinical models (Carter et al., 2016). Additionally, computational tools are employed to analyze the structural properties of viral proteins, identify conserved epitopes, and predict their immunogenic potential. This enables the design of epitope-focused vaccines that can elicit broadly neutralizing antibodies targeting conserved regions such as the HA stem and NA active sites (Qiu et al., 2019). Another key area where computational approaches excel is in the optimization of vaccine formulations. By simulating immune responses and predicting antigenic drift, researchers can refine vaccine candidates to enhance their efficacy and durability. Machine learning algorithms further assist in analyzing large datasets, including viral genomic sequences and immune responses, to identify patterns and predict the most effective vaccine combinations. These techniques have also been used to design multi-epitope vaccines that combine several conserved regions, thereby increasing the breadth and effectiveness of the immune response (Wong and Ross, 2016). Despite the advances, challenges remain in integrating these computational approaches with experimental validation. The complexity of immune responses and the dynamic nature of viral evolution require continuous refinement of models and predictions. Nonetheless, the integration of computational tools with traditional vaccine development methodologies holds great promise for creating a universal influenza vaccine that can provide comprehensive protection against future influenza pandemics (Xu and Li, 2024). 5 Role of Adjuvants in Enhancing Antigenicity Adjuvants play a crucial role in enhancing the immune response to vaccines by improving the antigenicity of vaccine components. They achieve this by promoting a stronger and more durable immune response, allowing for lower doses of antigen to be used while maintaining or even improving vaccine efficacy (Paules et al., 2017; Petrie and Gordon, 2018). 5.1 Molecular adjuvants Molecular adjuvants are small molecules or proteins that modulate the immune response by targeting specific pathways involved in immunity. These adjuvants can be designed to enhance both humoral and cellular immune responses, making them particularly valuable in the development of universal influenza vaccines. For example, the STING (Stimulator of Interferon Genes) pathway has been identified as a critical target for molecular adjuvants. Encapsulation of STING agonists, such as cyclic dinucleotides (CDNs), in microparticle delivery systems has shown significant promise. In one study, STING agonists encapsulated in acid-sensitive acetalated dextran microparticles (Ace-DEX MPs) dramatically enhanced type-I interferon responses and boosted antibody titers against influenza, demonstrating the potential of molecular adjuvants in vaccine design (Figure 1) (Junkins et al., 2018). Another study highlighted the use of glycosylphosphatidylinositol-anchored CCL28 and GM-CSF fusion proteins in virus-like particle (VLP) vaccines, which significantly improved humoral and cellular immune responses in mice (Liu et al., 2018).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==